Hyasynth Bio

Hyasynth Bio

A biology company based in Montreal, Canada with a main focus on engineering microbes for the manufacturing of pharmaceuticals and other products, specifically cannabinoids including THC.

Instead of growing plants to make cannabinoids, Hyasynth engineer strains of yeast to produce it. After the yeast strains grows, they isolate pure cannabinoids for research, or for products like oils and pills.

Hyasynth is a Licensed Dealer under the Narcotic Control Regulations of Health Canada. Under these regulations, Hyasynth is permitted to produce and distribute cannabinoid products to those that are also legally allowed to possess cannabinoid products.

Their stated goal is to create a new way of producing cannabinoids that doesn't depend on growing plants or doing synthetic chemistry.

There are many cannabinoids, terpenes and combinations of these compounds.

Hyasynth has raised over $1M. The lead investors were Anges Quebec, a local angel network that put in $392,000 from its members and their first round of investors, which include SOSV, Ethan O. Perlstein (CEO of Perlara), and Andrew Hessel from Autodesk.

Timeline

People

Name
Role
LinkedIn

Alex Campbell

Founder

Andrew Hessel

Advisor

Andrew Hessel

Investor

Bill Liao

Advisor

Ethan O. Perlstein

Advisor

Ethan O. Perlstein

Investor

Jesse Rasch

Investor

Julien Saulgrain

Attorney

Kevin Chen

Founder

Nuzhat Tam-Zaman

Advisor

Rajeev Krishnan

Investor

Rajeev Surati

Investor

Shoham Mookerjee

Founder

Tariq Warsi

Advisor

Zach Wiltshire

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.